The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
YONDELIS (Specialised Therapeutics Pharma Pty Ltd)
Product name
YONDELIS
Date registered
Evaluation commenced
Decision date
Approval time
193 (255 working days)
Active ingredients
trabectedin
Registration type
NCE/NBE
Indication
YONDELIS (powder for injection) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.